On May 20, 2020, Cidara Therapeutics, Inc. and Mundipharma issued a joint press release reporting that the first patient has been dosed in the ReSPECT Phase 3 clinical trial of rezafungin. A copy of the press release is filed as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Cidara Therapeutics, Inc. Exhibit
EX-99.1 2 ex9912020-05×20.htm PRESS RELEASE Exhibit Exhibit 99.1Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow TransplantationSAN DIEGO,…
To view the full exhibit click here

About Cidara Therapeutics, Inc. (NASDAQ:CDTX)

Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease.